In a phase 1b trial in CRC patients, the ORR was 62.5% (95% confidence interval: 40.6%, 81.2%) in KRAS G12C inhibitor-naive patients (n = 24), with a median duration of response of 6.9 months and an mPFS of 8.1 months (95% confidence interval: 5.5, 12.3). The gene discussed is KRAS; the disease is colorectal carcinoma.